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Key questions
What is already known?
 ► Africa fares very poorly regarding publications in 
research and innovation, where international col-
laboration for research conducted in Africa tends to 
under-represent African researchers yet secures key 
authorship for non-African researchers.
What are the new findings?
 ► Our study suggests that despite their significant 
contribution, African authors are highly under-rep-
resented as first and last authors in collaborative 
infectious disease research conducted within the 
African continent.
 ► Most of African first and last authors had affiliations 
in Anglophone countries.
What do the new findings imply?
 ► This calls for capacity building and equitable part-
nership between African countries and western na-
tions for scientific research and publication.
 ► There is a need for more efforts to include French-
speaking African researchers in research collabora-
tions and a need for an active valorisation of research 
studies published in French-written journals.
AbsTrACT
Introduction Africa contributes little to the biomedical 
literature despite its high burden of infectious diseases. 
Global health research partnerships aimed at addressing 
Africa-endemic disease may be polarised. Therefore, 
we assessed the contribution of researchers in Africa to 
research on six infectious diseases.
Methods We reviewed publications on HIV and malaria 
(2013–2016), tuberculosis (2014–2016), salmonellosis, 
Ebola haemorrhagic fever and Buruli ulcer disease (1980–
2016) conducted in Africa and indexed in the PubMed 
database using Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses protocol. Papers reporting 
original research done in Africa with at least one laboratory 
test performed on biological samples were included. We 
studied African author proportion and placement per study 
type, disease, funding, study country and lingua franca.
results We included 1182 of 2871 retrieved articles that 
met the inclusion criteria. Of these, 1109 (93.2%) had at 
least one Africa-based author, 552 (49.8%) had an African 
first author and 41.3% (n=458) an African last author. 
Papers on salmonellosis and tuberculosis had a higher 
proportion of African last authors (p<0.001) compared with 
the other diseases. Most of African first and last authors 
had an affiliation from an Anglophone country. HIV, malaria, 
tuberculosis and Ebola had the most extramurally funded 
studies (≥70%), but less than 10% of the acknowledged 
funding was from an African funder.
Conclusion African researchers are under-represented in 
first and last authorship positions in papers published from 
research done in Africa. This calls for greater investment 
in capacity building and equitable research partnerships at 
every level of the global health community.
InTroduCTIon
Africa faces a high burden from infectious 
diseases with, for example, 90% of all HIV 
and malaria deaths in children in developing 
countries occurring South of the Sahara.1 
Ebola and Buruli ulcer are neglected and 
under-researched diseases whereby progress 
towards preventive measures for them has 
been slow.2 The devastating effects of these 
infectious diseases and their potential to 
spread drive an international imperative 
to address them through research. Mutu-
ally beneficial partnerships between African 
countries and Western nations for scientific 
research and publication have the potential to 
improve research capacity and address global 
health challenges. Research in endemic areas 
also provides training and career develop-
ment opportunities for both African and 
Western scientists.
by copyright.
 o
n
 D
ecem
ber 2, 2019 at Universitaetsbibliothek Bern. Protected
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001855 on 18 October 2019. Downloaded from 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
59
99
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9
2 Mbaye R, et al. BMJ Global Health 2019;4:e001855. doi:10.1136/bmjgh-2019-001855
BMJ Global Health
In the past decades, international researchers are 
increasingly conducting clinical trials in low-income and 
middle-income countries (LMICs).1 Authors from the 
USA and Western Europe make up a striking 80% of the 
articles published in infectious diseases journals world-
wide.3 On the other hand, most low-income regions are 
tremendously under-represented in the research liter-
ature. The African continent produces only about 1% 
of the world’s research publications and 0.1% of global 
patents, and the bulk of publications emanate from just 
three countries.4 South Africa accounts for one-third 
of Africa's publication output, while Egypt and Nigeria 
jointly account for another one-third.5 6
African researchers commonly publish internationally 
in collaboration with Western scientists. Consequently, 
there has been a gradual increase in the volume of scien-
tific publications from and about Africa, with a notice-
able dominance by non-African coauthors.7 8 However, 
inequity in research partnerships can hinder true prog-
ress.9 For instance, collaborations across countries might 
create authorship disputes as a result of false expecta-
tions, unclear arrangements and poor communication 
between those concerned.10 Traditionally, at least in the 
biomedical sciences, the last author is usually an eminent 
professor or senior in the research field who is credited 
for leading the research, while the first author is usually 
the one who bears the highest day-to-day research work-
load for the project. Either the first or the last author 
coordinates the collaborative team and correspond with 
the journal through peer review.11 12
High-income country researchers control funding 
and therefore can dictate research agendas in Africa.13 
Accordingly, African authors could be under-repre-
sented in writing up collaborative work for publication 
and this is especially true for authorship positions of first 
or last authors which are sometimes driven by compe-
tition for resources and the desire for recognition.11 It 
is not clear to what extent imbalances in global health 
partnerships affect African authorship and positions in 
infectious disease research. To achieve success in global 
health research partnerships, it is an imperative to gain 
an understanding of the extent of the problem and 
address any concerns in authorship trends. This paper 
assesses authorship positions and the proportion of 
African researchers in medical research conducted in 
Africa. We also aim to compare proportions of lead and 
last authorship by study type, disease, study country and 
lingua franca of Africa-based lead and last authors.
MeTHods
We performed a systematic review of the primary biomed-
ical literature indexed in Medline (PubMed).14 Relevant 
elements of the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines were followed in 
conducting and reporting the findings of this review.15 Six 
diseases were selected as case studies for the assessment. 
We chose Africa-endemic diseases (Ebola haemorrhagic 
fever, malaria, Buruli ulcer); diseases that occur predom-
inantly but not exclusively in low-income settings (salmo-
nellosis) as well as infectious conditions of international 
concern that exert a predominant burden in Africa (HIV, 
tuberculosis).16–18 Our six case studies include diseases 
caused by viruses, bacteria and parasite, as well as easy 
and difficult to culture organisms. We also selected 
diseases for which there was a sufficient body of literature 
to provide power to analyses and diseases in which at least 
one member of our team had research expertise.
We performed independent searches for clinical trials 
and epidemiological studies done in Africa on each of 
the six selected diseases, that is, HIV, malaria, tubercu-
losis, salmonellosis, Ebola and Buruli ulcer. Of the six 
diseases, three are moderately researched in Africa, 
based on their hits on PubMed between 1980 and 2016. 
The other three were highly researched infectious 
diseases (HIV, malaria and tuberculosis). These yielded 
a higher number of hits in the same period—5716, 3421 
and 1685, respectively—and hence were researched 
for shorter periods for the purpose of this study. Thus, 
among clinical trials and epidemiological studies done 
in Africa, all papers on tuberculosis published between 1 
August 2013 and 31 July 2016 and all papers on malaria 
and HIV, published between 1 August 2014 and 31 July 
2016, were extracted from PubMed. In addition, all clin-
ical trials and epidemiological studies done in Africa 
on salmonellosis, Buruli ulcer and Ebola, published 
between 1 August 1980 and 31 July 2016, were extracted 
from PubMed.
Separate searches were performed to retrieve papers 
reporting clinical trials and epidemiological findings for 
all six diseases. Specific key search terms were systemati-
cally used using all the different possible combinations 
between the types of studies (clinical and epidemiolog-
ical), the different diseases (HIV, malaria, tuberculosis, 
salmonellosis, Ebola and Buruli) and all the 54 African 
countries in addition to the word Africa. A sample of one 
possible combination considering the types of study as 
‘epidemiological’, ‘Ebola’ as the chosen disease and the 
‘list of African countries’ would look like:
I. ‘Epidemiology OR Epidemiological’ AND 
Laboratory
II. ‘Ebola’ AND
III. Africa OR Algeria OR Angola OR Benin OR Botswana 
OR Burkina Faso OR Burundi OR Cameroon OR 
Cape Verde OR Central African Republic OR Chad 
OR Comoros OR Congo OR Cote d'Ivoire OR 
Democratic Republic of the Congo OR Djibouti 
OR Equatorial Guinea OR Eritrea OR Ethiopia OR 
Egypt OR Gabon OR Gambia OR Ghana OR Guinea 
OR Guinea-Bissau OR Kenya OR Lesotho OR 
Liberia OR Libya OR Madagascar OR Malawi OR 
Mali OR Morocco OR Mauritius OR Mauritania OR 
Mozambique OR Namibia OR Niger OR Nigeria OR 
Rwanda OR Soa Tome and Principe OR Senegal OR 
Seychelles OR Sierra Leone OR Somalia OR South 
Africa OR Sudan OR South Sudan OR Swaziland OR 
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Figure 1 Flow chart of study selection. 
Three moderately researched diseases in Africa 
(salmonellosis, Ebola and Buruli; 1980–2016) and three highly 
researched diseases in Africa (tuberculosis, 2013-2016; and 
HIV and malaria, 2014–2016).
Togo OR Tunisia OR Uganda OR United Republic 
of Tanzania OR Zambia OR Zimbabwe
An article was selected for inclusion in the study if it 
was a primary research paper reporting original research 
done in Africa and included at least one laboratory test 
result, with biological sample collected or processed in 
Africa. Biological samples included blood (including 
dried blood spots), urine, stool, biopsies and swabs 
(throat, anal, vaginal, and so on). Studies that evaluated 
behaviours, archival specimens and isolates in addition to 
studies based on plant, water, environmental and animal 
samples were excluded. Review papers, editorials and 
opinion papers that did not contain primary data were 
also not eligible for this study. Concerning authorship, 
only first and last authorship were examined. Corre-
sponding authors were excluded as they are not always 
first or last authors. Given that further information to 
guide assignment of institution is not practically available 
for a review of this nature. The country of affiliation for 
the author was assigned based on listed institution on 
the paper. When authors had multiple affiliations that 
included an African country, they were assigned to the 
African affiliation for the purpose of the study.
Based on reading of the abstracts, articles were 
confirmed to be either a clinical trial or an epidemio-
logical study and then doubly assessed by two reviewers 
against the inclusion and exclusion criteria. A third 
reviewer with expertise on the relevant diseases reevalu-
ated the list of included and excluded studies based on 
the eligibility criteria to make a final decision on the list 
of articles included for analysis. From the final included 
list of studies, data related to authorship, country of 
affiliation, reception of funding and language spoken by 
authors (based on country of affiliation) were compiled 
in a study database. Data were cleaned to standardise the 
terms used for analysis and reporting. We used R Studio 
(V.1.0.153) data analysis software to estimate proportions, 
CI and hypothesis testing, as well as generate descriptive 
plots. We also used R Studio to compare the proportion 
of African first and/or last authors to non-African per 
study type, disease, country and language. The tests were 
two-tailed. Any difference was considered significant if 
the p-value was <0.05.
Patients and public involvement
No patients were involved on this study.
resulTs
Articles included in the analysis
We retrieved 2871 articles that included both clinical 
trials and epidemiological studies on HIV, malaria, tuber-
culosis, salmonellosis, Ebola and Buruli conducted in 
Africa. Of these, 1182 articles met the inclusion criteria 
for the study (figure 1). Overall, we had a 41.2% inclusion 
rate with disease-specific rates being: malaria: 325/554 
(58.7%), tuberculosis: 230/561 (41.0%), HIV: 386/1123 
(34.4%), Ebola: 77/332 (23.2%), salmonellosis: 134/254 
(52.8%) and Buruli: 30/47 (63.8%) (figure 1). Regarding 
study type, 502 out of 1182 (42.5%) of articles included 
were clinical trials, while the remaining 680 (57.5%) 
represent epidemiological studies. Most of the reviewed 
articles were on HIV (n=386), malaria (n=325) and 
tuberculosis (n=230), with salmonellosis (n=134), Ebola 
(n=77) and Buruli (n=30) expectedly yielding fewer 
papers (figure 2). The proportion of studies with labora-
tory tests performed in Africa ranged from 68% to 90% 
across the six diseases under study.
African authorship
Of the 1182 articles included, 1109 (93.2%) had at least 
one author affiliated to an African institution (AI). 
Approximately half (n=552, 49.8%) of all the articles 
reviewed had a first author affiliated to an AI, while 
41.3% (n=458) had a last author affiliated to an AI.
number of African countries involved in research done in 
Africa and African authorship per disease
Table 1 lists the general characteristics of the articles 
included in this analysis. Researchers from more African 
countries published on malaria research than any of the 
other diseases,19 followed by salmonellosis20 and HIV.21 
Across most of the diseases studied, well under half of 
the articles had Africans as first or last authors (table 1). 
For Ebola, only 25% of authors in these lead positions 
were Africans. Salmonellosis had a higher proportion 
of lead African authors (0.7, CI 0.62 to 0.78) compared 
with other five diseases, and more than double of the 
other two moderately researched diseases (ie, Ebola 
and Buruli). The proportion of African last authors for 
HIV (0.36, CI 0.31 to 0.41) and malaria (0.37, CI 0.31 to 
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Figure 2 Number of articles included in the study by 
disease, in the order of publication volume, and reflecting 
study types (clinical trials and epidemiological studies). 
The numbers on top of each bar represent the percentage of 
clinical trials from all studies included per disease.
0.42) is significantly lower than the proportion of African 
first authors in those two diseases, respectively (0.51, CI 
0.46 to 0.56) and (0.55, CI 0.49 to 0.60). The opposite is 
observed in tuberculosis with the proportion of African 
last authors (0.53, CI 0.46 to 0.59) being higher in this 
case than the proportion of African first authors (0.37, 
CI 0.31 to 0.44).
Funding source
In terms of extramural funding (table 1), salmonellosis 
was the disease with the lowest proportion of studies 
acknowledging financial support (0.48, CI 0.39 to 0.57). 
HIV, malaria, tuberculosis and Ebola had high percent-
ages of studies that reported receiving funding (greater 
than 70%), but under 10% of the acknowledged funding 
was from African country sources. As suggested by the 
coinciding CIs, whether or not the first or last authors 
are affiliated to AI does not seem to affect the reception 
of funding.
Proportions of first and last African vs non-African authors 
based on authors’ countries of affiliation
As demonstrated in figure 3, salmonellosis research has 
the highest proportion of African last authors (7 out of 
10), followed by HIV and malaria (5 out of 10 each), 
Ebola (4 out of 10), tuberculosis (3 out of 10) and Buruli 
(2 out of 10). With the exception of salmonellosis and 
tuberculosis, all other diseases have a statistically signif-
icant higher proportion of last authors from non-AIs 
(p<0.001). Both highly researched and moderately 
researched diseases have a higher proportion of non-Af-
rican last authors (ie, 64.0% and 59.7%; p≤0.001). The 
non-African countries that dominated last authorship 
positions in African endemic disease research are the 
USA, the UK, France, Belgium and Germany (figure 4). 
China’s involvement is mostly focused on Ebola, while 
countries like the USA, the UK, France and Belgium are 
represented across all diseases. African countries with the 
greatest representation of last authorships are South-Af-
rica, Ethiopia, Nigeria, Kenya and Ghana (figure 4). As 
with first authorships, there was some skew seen towards 
endemic countries for malaria and Buruli ulcer diseases.
Authorship versus study types and lingua franca
In figure 5, the inner circle shows the proportion of the 
reviewed articles focusing on the six diseases, the middle 
circle shows the proportion of the articles describing 
research from an epidemiological or a clinical perspec-
tive for each disease. The outer circle shows the origin of 
the author separated by ‘African’ origin versus ‘Non-Af-
rican’ origin per study type and disease.
As shown in figure 5A, out of the six diseases, only Ebola 
and tuberculosis have a significantly lower proportion of 
African first authors in clinical trials papers than non-Af-
rican first authors with p-values<0.001 for both diseases. 
Salmonellosis, on the other hand, while having many fewer 
clinical trials overall, has a significantly higher proportion 
of African first authorships in clinical trials (p=0.025). 
Tuberculosis and HIV, highly researched diseases of inter-
national significance, have a significantly lower proportion 
of African first authors (p<0.001 and p=0.019, respectively). 
As figure 5B displays, aside from salmonellosis and tuber-
culosis, all other four diseases have a significantly higher 
proportion of non-African last authors as compared with 
African authors in clinical trials studies (p=0.027). Addi-
tionally, the proportion of African last authors in clinical 
trials is lower than that of African last authors in epidemio-
logical studies (30.2 vs 46.1% p=0.027).
We assessed the representation of lingua franca of the 
countries to which first and last authors from AIs are affil-
iated (figure 6). The inner circle shows the proportion 
of the reviewed articles focusing on the six diseases, the 
second circle shows the origin of the author separated 
by ‘African’ origin versus ‘Non-African’ origin for each 
disease, the third circle shows the proportion of ‘one of 
the official languages’ of the countries of the author’s 
origin for the authors with African origin and the outer 
circle shows the proportion of the country where most 
of the articles were published versus all other coun-
tries among the most common official language of the 
author’s country of origin.
For all six diseases considered, first (figure 6A) and 
last authors (figure 6B) are predominately drawn from 
Anglophone countries, with differences in proportions 
giving statistically significant p<0.001. This is true for both 
first and last authors for HIV, tuberculosis and salmonel-
losis, and for first authors only for malaria and Buruli, 
the two endemic diseases with endemic foci in only some 
countries. Francophone countries are more likely to have 
lead authorships for those two diseases as compared with 
other diseases, while authors affiliated to Arabic-speaking 
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Table 1 Summary and comparison of the study outcomes for all six diseases
HIV Malaria Tuberculosis Salmonellosis Ebola Buruli
Period of 
Publication 
Evaluated
August 1, 2014 to 
July 31, 2016
August 1, 2014 to 
July 31, 2016
August 1, 2013 to 
July 31, 2016
August 1, 1980 to 
July 31, 2016
August 1, 1980 to 
July 31, 2016
August 1, 1980 to 
July 31, 2016
Number of articles 
included after final 
review
386 325 230 134 77 30
Number of African 
countries from 
which studies 
were done
25 33 26 28 9 7
Proportion 
of studies 
with African 
Researchers
0.48 (0.46–0.49) 0.55 (0.54–0.57) 0.56 (0.54–0.58) 0.64 (0.61–0.67) 0.25 (0.23–0.27) 0.45 (0.39–0.51)
Proportion of 
studies with first 
authors from 
African Institutions
0.51 (0.46–0.56) 0.55 (0.49–0.6) 0.37 (0.31–0.44) 0.71 (0.62–0.78) 0.29 (0.19–0.4) 0.33 (0.18–0.53)
Proportion of 
studies with last 
authors from 
African Institutions
0.36 (0.31–0.41) 0.37 (0.31–0.42) 0.53 (0.46–0.59) 0.64 (0.55–0.72) 0.23 (0.15–0.35) 0.17 (0.06–0.35)
Proportion of 
studies that 
acknowledged any 
funding source(s)
0.8 (0.76–0.84) 0.88 (0.84–0.91) 0.71 (0.65–0.77) 0.48 (0.39–0.57) 0.64 (0.52–0.74) 0.87 (0.68–0.96)
Proportion of 
studies that 
acknowledged 
funding from 
African Institutions
0.05 (0.03–0.08) 0.08 (0.06–0.12) 0.09 (0.06–0.13) 0.01 (0–0.06) 0.13 (0.07–0.23) 0.07 (0.01–0.24)
Proportion of 
studies that 
acknowledged 
funding when first 
author is from 
African Institutions
0.74 (0.67–0.8) 0.86 (0.8–0.91) 0.73 (0.62–0.82) 0.44 (0.34–0.55) 0.5 (0.31–0.69) 0.8 (0.44–0.96)
Proportion of 
studies that 
acknowledged 
funding when last 
author is from 
African Institutions
0.74 (0.66–0.81) 0.79 (0.7–0.86) 0.65 (0.56–0.74) 0.45 (0.35–0.56) 0.39 (0.18–0.64) 0.6 (0.17–0.93)
Proportion of 
studies with 
laboratory tests 
done in Africa
0.74 (0.7–0.79) 0.79 (0.74–0.84) 0.9 (0.85–0.93) 0.68 (0.59–0.76) 0.78 (0.67–0.86) 0.83 (0.65–0.94)
The total number of articles for each disease is analysed by number of articles, place of research and lab test, first and last authorship, 
and funding availability.
The general characteristics of the articles included in the analysis based on the six diseases with the mean of the sample estimate and 
confidence interval at a 95% confidence level represented in brackets.
AIn, African Institutions; AR, African Researchers.
countries are more involved in salmonellosis research than 
other diseases. For practically all the diseases, lingua franca 
data are skewed towards specific countries such as South 
Africa and Kenya for Anglophone countries regarding HIV 
and tuberculosis, while Burkina Faso and Cameroon skew 
data for Francophone countries in malaria.
dIsCussIon
This study assessed authorship in publications reporting 
scientific findings from the highly researched malaria, 
HIV and tuberculosis, as well as from moderately 
researched diseases salmonellosis, Ebola haemorrhragic 
fever and Buruli ulcer. Overall, of the articles included, 
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Figure 3 Number and proportion of first authors by 
country for each of the six diseases: (A) HIV (B) malaria (C) 
tuberculosis (D) salmonellosis (E) Ebola, and (F) Buruli. 
Each graph displays the top 10 countries represented by 
the first authors of the articles included for each disease in 
terms of frequency (on the left axis) denoted by the bars and 
proportions of first authors (on the right axis).
Figure 4 Number and proportion of last authors by country 
for each of the six diseases examined: (A) HIV (B) malaria (C) 
tuberculosis (D) salmonellosis (E) Ebola, and (F) Buruli. 
Each graph displays the top 10 countries represented by 
the last authors of the articles included for each disease in 
terms of frequency (on the left axis) denoted by the bars and 
proportions of last authors (on the right axis).
only 93.2% had any African authors represented. While 
this number is high, it points to almost 8% of articles 
from Africa using Africa-collected specimens that lack a 
co-investigator that meets the International Committee 
of Medical Journal Editors authorship criteria.22 Of those 
that did include an African author, only 49.8% had an 
African first author and 41.3% had an African last author. 
There is a geographical inequity in the representation of 
African first and last authors involved in highly and moder-
ately researched infectious disease research. Anglophone 
countries like South-Africa, Ethiopia, Nigeria, Kenya and 
Ghana are the most represented countries of origin of 
African first and last authors.
Authorship representation and positioning provide 
one method of measuring African participation and lead-
ership in research, as well as the possibility for Africans 
to negotiate decision-making in collaborative research 
performed in their countries. The data presented in 
this paper demonstrate that for research on endemic 
infectious diseases conducted on the continent, African 
collaborators are an almost ubiquitious piece of the 
discovery effort but do not commonly feature in the lead 
authorship positions. Much of the research conducted 
in sub-Saharan Africa is through international collabo-
rations. In 2012, 79%, 70% and 45% of all research by 
Southern Africa, East Africa and West and Central Africa, 
respectively, were produced through international 
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Figure 5 First and last authors per each of the six diseases 
and by study types (epidemiological or clinical). 
Each sunburst displays the repartition of first and last African 
vs Non-African researchers per type of study (clinical vs 
epidemiological) for each disease.
Figure 6 First and last authors per each of the six diseases 
and by languages (Anglophone, Francophone and Arabic). 
Each sunburst displays the repartition of first and last African 
vs Non-African researchers for each disease per language 
and including the most represented African country.
collaborations.23 These collaborations are mostly with 
non-African partners and could involve unequal partner-
ships. Our own research shows that only a minority of 
articles have Africans as first and last authors.
A number of studies report similar findings. Lyer 
analysed authorship trends in the Lancet Global Health 
and found that the majority of studies published are 
conducted in Africa (40%) with scanty LMIC authorship 
contribution (44%) for articles from Africa. However, 
this study did not break down the analysis and it was 
restricted to the Lancet Global Health Journal only. 
The analysis was performed by a single author therefore 
could have been erroneous.24 Similarly, Rees and collab-
orators found a trivial authorship contribution from 
LMICs (15.5%) and LICs (5.4%) authors to paediatric 
research conducted in LMICS.25 There is evidence that 
lead authorship has increased in LMICs but this is not 
significant. Chersich et al mapped authorship of maternal 
health interventional research in LMICs and they found 
that only 25% of LMIC lead the majority of their research 
(75%). In summary, approximately half of authors with 
LMICs affiliation lead research conducted in their coun-
tries. When analysed by study type, authorship lead was 
drastically low for systematic reviews (26.8%), modelling 
studies (29.9%) and for articles published in journals with 
a high impact factor (>5) (33.2%).26 Again, there was no 
comprehensive description of authorship by country nor 
lingua franca as provided in the current study. Several 
other studies report discrepancies in data proprietorship 
for studies conducted in the LMICs.21 27 28
Ebola and Buruli ulcer are solely or largely found in 
some zones of Africa, respectively. It has been observed 
that African authors working on Buruli ulcer are more 
likely to work towards health-related outcomes.29 The 
fact that 7 out of the 10 top countries of first authors 
conducting studies on Ebola and Buruli in Africa are 
non-African points to a dearth of African leadership 
in these areas that may in fact connect to the slow rate 
of outcomes. We note that ethnography on neglected 
diseases and their neglected actors recorded the testi-
mony of local professionals, who have long experi-
ence with Buruli ulcer frustrated of being, in the best 
cases, merely ‘acknowledged’ in a footnote to the final 
publications.30
For most highly researched diseases, the story is not 
much different. The proportion of African last authors 
is also particularly lower than the proportion of African 
first authors for HIV and malaria. In fact, with the 
exception of salmonellosis, five of the six diseases have 
a higher proportion of non-African last authors, with 
senior authorships predominantly from the USA, the UK, 
France, Belgium and Germany. Within Africa, research 
leadership as computed from first and last authorships 
mostly comes from only six countries: South Africa, Ethi-
opia, Nigeria, Kenya and Ghana. If we take out these star 
researcher countries, which themselves mostly include 
only a handful of star researchers, very little research 
leadership is evidenced across the continent.
Our study revealed that African Anglophone coun-
tries dominate as first and last authors of papers for all 
six diseases studied. This finding could be as a result of 
international scientific collaboration which in many cases 
is conducted in English.23 Additionally, tropical medi-
cine, as a research discipline, has roots in colonial Britain 
and was critical to the attainment of the colonial British 
agenda.20 31 32 While there are no more British colonies in 
Africa, decolonisation does not appear to have brought 
local ownership or credit for biomedical research on 
African disease even though it may explain some of the 
ascendancy of Anglophone countries when it comes 
to infectious disease research. This, notwithstanding, 
France, Belgium and Germany are also important 
contributors to Africa endemic area research. We also 
found out that francophone countries are more involved 
in malaria research. This could be pertaining to three 
primary reasons: first, West Africa, which is predomi-
nately francophone, is disproportionally affected by 
malaria, and accounts for half of the global burden.33 
Second, the shared factor among West African countries 
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is almost certainly their common use of French, which 
makes scientific collaboration to be driven strongly by 
language.34 Finally, the Institute Pasteur Network labora-
tories in Africa, predominantly located in Western and 
Central Africa, have a strong focus in malaria.19 This 
third critical factor again points to colonial heritage and 
links as the chief factor underpinning research leader-
ship across the continent. Similar collaborative patterns, 
but at lower levels were seen for Buruli ulcer, which has 
endemic foci in Cameroon and Benin. Nigeria may act as 
a bridge between Anglophone and Francophone areas, 
making its international collaboration rate higher.7
Although previous studies have also analysed research 
output trends in authorship proportions and compari-
sons,21 24–28 this is the first report, to our knowledge, that 
provides comprehensive analysis of first and last author-
ship assessments between African and non-African groups 
as well as assessment of high profile versus endemic 
diseases. However, our study is not without limitations. 
For instance, one limitation of the study was that most 
of the analysis was done manually; however, this was 
counterbalanced by having at least three authors assess 
each paper. Manual analysis made it impossible to deter-
mine temporal authorship patterns for more than three 
diseases. Additionally, for highly researched diseases, our 
search was necessarily limited to the period between 2014 
and 2016 and could not be compared over the same time 
frame (1980 to 2016) due to the large number of publi-
cations available for infectious diseases like HIV, malaria 
and tuberculosis. As such, there was a limited consistency 
in the search strategy. Another limitation was our exclu-
sion of ‘corresponding authors’—who are lead authors 
that are often but not always first or last authors.35 More-
over, it was challenging to find out the nationality of the 
author as we wanted to represent the country of affiliation 
in our results. Using institutional affiliation as a proxy for 
nationality or country of origin will have led to misclas-
sifications. For example, an African researcher working 
on malaria but based in an institution in the UK would 
be included in the non-African group. Thus, our study 
discounts Africa’s large scientific diaspora, classifying 
them as non-Africans unless they declared an African 
affiliation. Similarly, a non-African researcher with an 
African affiliation would have been classified as African 
for the purpose of our study. Altogether, our method-
ology will have produced an over-reporting of African 
scientists and would therefore overestimate the relatively 
low rates of African authorship recorded. Finally, by 
using only PubMed as the sole database for our article 
sources, our assessment of lingua franca might also have 
been biased towards English.
Collaboration can benefit all sides and serve common 
interests by producing excellent research which can help 
expand scientific knowledge as well as communicate the 
work through joint publications. While such collabora-
tion and the necessary divisions of tasks are constructive, 
there may be grey areas in responsibility sharing and/
or less than fair11 representation in published journals. 
Thus, it is important to realise that while Westerners may 
bring funding and/or technical expertise, the necessary 
context those local researchers should bring, among 
other contributions, may be lacking. This has overall 
consequences for the quality of the research and the bene-
fits it can bring. Lopsidedness in funding is often blamed 
for research participation inequities. Increased interest 
and investment in African-led research by funding and 
scientific institutions from the USA and Europe, and the 
recent establishment of a continental funding presence 
in the form of the Alliance for Accelerating Excellence in 
Science in Africa (AESA) are all aimed at creating strong 
academic partnerships and to leveraging the devel-
opment of technological solutions to Africa-endemic 
diseases. Our evaluation periods ended in 2016 and it 
remains to be seen whether a future study of this nature 
performed after these initiatives are well established will 
detect significant improvements in research equity and 
African leadership in publications.
Funding is however not the only factor driving lead-
ership. African scientists and academic societies need to 
engender more visibility for local and locally led research 
by publishing it in the indexed literature. There also 
needs to be a greater local investment in ethical and 
regulatory policies to support career development and 
insist on equity as well as to build the articulation skills 
needed for proposal and paper writing and research 
leadership. AIs also must be mindful of the issue at hand 
and must avail African researchers protected time and 
support to meaningfully be involved in research and 
not just named co-investigators on grants and studies. 
African researchers should be involved in the conduct 
of research from conception to dissemination of results, 
thereby making significant inputs. Research funding 
institutions could help by insisting on shared authorship 
or an explanation when this is not possible, when they 
fund partnerships.
Science and technology study investigators that have 
evaluated partnerships have often found that AIs provide 
field sites, patients, samples and data, while Western part-
ners provide funds and technical expertise (especially 
for data analysis, interpretation and writing).36 37 Many 
of these reports are based on empiric data although of 
limited in scope and location.29 Our findings in this study 
were that for all the diseases studied, most of the biolog-
ical testing takes place on the continent but much of the 
credit for publication leadership is elsewhere. Therefore, 
while the full contribution of Africans to science is yet to 
be quantified, local scientific activity is taking place.
ConClusIon
The results of our study showed that African researchers 
are under-represented in the most important positions 
(ie, first and last authorship positions) on papers from 
research performed in Africa. Within Africa, certain 
geographical areas, particularly non-Anglophone ones 
are further under-represented. We also found that the 
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representation varies per diseases and also study types. To 
address this challenge, there is an opportunity to build 
more research capacity using African funds while imple-
menting more equitable partnership to ensure African 
researchers are telling their story.
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